Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan, China And Korea To Work Together Towards Clinic Trials Data Sharing

This article was originally published in PharmAsia News

Executive Summary

Drug regulatory directors from Japan, China and Korea held a joint meeting in Tokyo April 14 to promote sharing clinical trial data among the three countries. Japan's Pharmaceutics and Food Safety Bureau Chief and directorial officers from the Korean FDA and China's State FDA agreed to exchange information and to conduct a joint research project on the difference in ethnicities, the biggest barrier to sharing clinical trials data. The three countries also set up a working group to promote joint research projects. (Click here for more - Japanese language

You may also be interested in...

Insider Analysis From Fountain Medical Development: Clinical Development in China - Current Status And Future Trends

By Joanne Jiang, Ph.D, Fountain Medical Development Ltd

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts